Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa
Award amount
$289,823Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ORGANIX CHEMISTRY SOLUTIONS LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HEGURQ5WJRQ9
- Solicitation number
- PA12-088
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Targeting Breast Cancer Metastasis with Id1
- Targeting Breast Cancer Metastasis with Id1
- Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment
- The first reversible radioligand for the hVMAT2 [3H]reserpine binding site
- Benzodiazepine Analogs as Novel Treatments for Catatonia
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
15 SBIR/STTR records share this UEI (1995–2017). Reported award amounts total $6,742,699. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services